Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia
Vaccine, Volume 26, No. 29-30, Year 2008
Notification
URL copied to clipboard!
Description
This study aimed to determine the immunogenicity of a 9-valent pneumococcal conjugate vaccine (PCV-9) in a subgroup of Gambian children enrolled in a large vaccine efficacy trial. To place the antibody results in context, in this paper we also report previously unpublished data on serotype-specific clinical vaccine efficacy from the main trial. In the sub-study, a single 2-4 ml venous blood specimen was collected from 212 Gambian children 4-6 weeks after the administration of a third dose of PCV-9 or placebo. IgG antibodies to pneumococcal serotype 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F polysaccharides were measured by ELISA. The proportions of infants with antibody concentrations above 0.2, 0.35 and 1.0 μg/ml, and the geometric mean concentrations (GMCs) of anti-pneumococcal polysaccharide antibodies were substantially higher for each serotype in children who received three doses of PCV-9 than those in the placebo group. Among PCV-9 recipients, GMCs ranged between 2.61 and 11.09 μg/ml with the highest being against serotype 14 and the lowest against 9V polysaccharide. The estimated overall protective antibody level for all nine serotypes, based on the vaccine efficacy against vaccine-type invasive pneumococcal disease (IPD) of 77% (95% CI: 51, 90) observed in the trial, was 2.3 μg/ml (95% CI: 1.0, 5.0). The PCV-9 studied was immunogenic in a Gambian population where it was also found to be efficacious. © 2008 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Saaka, Mark
Unknown Affiliation
Okoko, Brown Jacob
Unknown Affiliation
Kohberger, Robert C.
Unknown Affiliation
Jaffar, Shabbar S.
Unknown Affiliation
Enwere, Godwin C.
Unknown Affiliation
Biney, Ekow
Unknown Affiliation
Oluwalana, Claire
Unknown Affiliation
Vaughan, Adeola
Unknown Affiliation
Zaman, Syed M.A.
Unknown Affiliation
Asthon, L.
Unknown Affiliation
Goldblatt, David L.
Unknown Affiliation
Greenwood, Brian M.
Unknown Affiliation
Cutts, Felicity T.
Unknown Affiliation
Adegbola, Richard A.
Unknown Affiliation
Statistics
Citations: 53
Authors: 14
Affiliations: 5
Identifiers
Doi:
10.1016/j.vaccine.2008.04.066
ISSN:
0264410X
Research Areas
Maternal And Child Health
Study Design
Cross Sectional Study
Study Locations
Gambia